Published in

Elsevier, Neurología, 3(31), p. 195-207, 2016

DOI: 10.1016/j.nrl.2013.04.011

Elsevier, Hipertensión y Riesgo Vascular, 4(30), p. 143-155, 2013

DOI: 10.1016/j.hipert.2013.04.003

Elsevier, Clínica e Investigación en Arteriosclerosis, 3(25), p. 127-139, 2013

DOI: 10.1016/j.arteri.2013.03.003

Links

Tools

Export citation

Search in Google Scholar

Comentarios del Comité Español Interdisciplinario de Prevención Cardiovascular (CEIPC) a las Guías Europeas de Prevención Cardiovascular 2012

Journal article published in 2013 by Royo-Bordonada,Miguel Ángel, Miguel Angel Royo-Bordonada ORCID, José María Lobos Bejarano, Lobos Bejarano,José María, José María Lobos Bejarano, Fernando Villar Alvarez, Villar Alvarez,Fernando, Fernando Villar Alvarez, Sans,Susana, Susana Sans, Antonio Pérez, Pérez,Antonio, Juan Pedro Botet, Botet,Juan Pedro, Juan Pedro-Botet and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Based on the two main frameworks for evaluating scientific evidence (SEC and GRADE) European cardiovascular prevention guidelines recommend interventions across all life stages using a combination of population-based and high-risk strategies with diet as the cornerstone of prevention. The evaluation of cardiovascular risk (CVR) incorporates HDL levels and psychosocial factors, a very high risk category, and the concept of age-risk. They also recommend cognitive-behavioural methods (e.g., motivational interviewing, psychological interventions) led by health professionals and with the participation of the patient's family, to counterbalance psychosocial stress and reduce CVR through the institution of positive habits such as a healthy diet, physical activity, smoking cessation, and adherence to treatment. Additionally, public health interventions — such as smoking ban in public areas or the elimination of trans fatty acids from the food chain — are also essential. Other innovations include abandoning antiplatelet therapy in primary prevention and the recommendation of maintaining blood pressure within the 130-139/80-85 mmHg range in diabetic patients and individuals with high CVR. Finally, due to the significant impact on patient progress and medical costs, special emphasis is given to the low therapeutic adherence levels observed. In sum, improving cardiovascular prevention requires a true partnership among the political class, public administrations, scientific and professional associations, health foundations, consumer associations, patients and their families. Such partnership would promote population-based and individual strategies by taking advantage of the broad spectrum of scientific evidence available, from clinical trials to observational studies and mathematical models to evaluate population-based interventions, including cost-effectiveness analyses.